学科专长和研究方向:
主要研究领域为泌尿系肿瘤、泌尿微创外科及前列腺疾病。近年来,作为主要负责人参与基因工程制药,腹腔镜器械研发www.lindalemus.com,医学可视化技术等工作。
在研的主要项目:
saRNA上调Par-4基因表达的若干机制及其治疗前列腺癌的实验研究(国家自然科学基金,30973466)
saRNAs上调前列腺癌中若干肿瘤抑制基因表达的机制研究(浙江省自然科学基金重点项目,Z2090356)
RNAs基因激活技术筛选前列腺癌靶标及其作用的研究 (国家自然科学基金,30772176)
荧光原位杂交技术检测膀胱癌分子细胞遗传学变异的临床应用研究(卫生部)
TGF-β受体缺陷型基因转染肿瘤特异性CD8+细胞治疗膀胱癌的研究(省部共建)
前列腺增生症及其合并症合理化治疗方案的研究(国家科技支撑计划, 2006BAI02B00)
代表论文:
1. Li Y, Yang K, Mao Q, Zheng X, Kong D, Xie L*. Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase. Int Urol Nephrol. 2009 Aug 8. [Epub ahead of print]
2. Mao Q, Zheng X, Jia X, Wang Y, Qin J, Yang K, Bai Y, Xie L*. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Nephrol. 2009 Feb 18. [Epub ahead of print].
3. Yan TZ, Jin FS, Xie LP, Li LC. Relationship between Glucocorticoid Receptor Signal Pathway and Androgen-Independent Prostate Cancer. Urol Int. 2008; 81: 228-233.
4. Mao QQ, Li YB, Zheng XY, Yang K, Shen HF, Qin J, Bai Y, Kong DB, Jia XL, Xie LP*. Up-regulation of E-cadherin by small activating RNA inhibits cell invasion and migration in 5637 human bladder cancer cells. Biochem Biophys Res Commun. 2008, 375(4): 566-570.
5. Jiang J, Zheng X, Qin J, Zheng M, Mao Q, Zhang Z, Cai S, Xie L*. Health-related quality of life after hand-assisted laparoscopic and open radical nephrectomies of renal cell carcinoma. Int Urol Nephrol. 2009; 41(1):23-7.
6. Zheng XY, Xie LP*, Wang YY, Ding W, Yang K, Shen HF, Qin J, Bai Y, Chen ZD.The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL.J Cancer Res Clin Oncol. 2008 Nov; 134(11): 1207-10.
7. Yang K, Zheng XY, Qin J, Wang YB, Bai Y, Mao QQ, Wan Q, Wu ZM, Xie LP*. Up-regulation of p21 (WAF1/Cip1) by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. Cancer Lett. 2008 Jul 8; 265(2): 206-214.